About Rakhshita Dhar
Rakhshita Dhar, MS, heads healthcare venture investments at Leaps by Bayer, which she joined in 2021. She joined SonoThera's board when Leaps by Bayer invested in its $125 million Series B in June 2026.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Rakhshita Dhar in the role, so the role may have started earlier or lasted longer.
LB
Leaps by Bayer Current
Vice President & Head, Healthcare Venture Investments
2021 – Present
NextPoint Therapeutics, Inc.
Board Member
2022 – 2026 · Cambridge, MA
Develops targeted cancer treatments for patients with solid tumors.
SonoThera, Inc.
Director
2026 · South San Francisco, CA
SonoThera develops nonviral genetic medicines that use ultrasound and imaging microbubbles to deliver DNA and RNA into chosen organs, starting with Duchenne muscular dystrophy.
RP
Roche Pharmaceuticals
Director of Business Development
MA
MassBio
CB
Cellino Bio
Board member
SB
Sudo Biosciences
Board member
AT
Affini-T Therapeutics
Board member
BS
Bloom Science
Board member
Education
- Undergraduate degree, Biochemistry, Mumbai University
- Master's, Molecular Biology, Georgetown University
Key Colleagues at Startups
The people Rakhshita Dhar works with at each company, as listed on that company's latest Form D.
NextPoint Therapeutics, Inc. · Form D, Jul 30, 2026
Paulina Hill
Board Member
Ivan Cheung
Chief Executive Officer and director
R. Jacob Vogelstein
Board Member
JL
Jeffrey Lacey
Secretary & Treasurer
Brian Shuster
Board Member
Detlev Biniszkiewicz
Chairman of the Board
Axel Hoos
Board Member
SonoThera, Inc. · Form D, Jun 30, 2026
SF
Steven Feinstein
Co-founder & Chief Scientific Officer
KG
Kenneth Greenberg
Co-founder, President & CEO, director
MD
Michael Davidson
Co-founder & Executive Chairman
RJ
Rajul Jain
Director
SG
Steven Gillis
Director
CZ
Carolyne Zimmermann
Chief Business Officer
BH
Brian Halak
Director
Recode Therapeutics, Inc. · Form D, Oct 23, 2025
RH
Rana Al-Hallaq
Director
PM
Patricia Millican
Director
SS
Shehnaaz Suliman
Executive officer and director
EH
Edward Hurwitz
Director
AC
Alan Colowick
Director
DL
David Lockhart
Executive officer
DM
Dean Mitchell
Director
BZ
Basheer Zada
Director
IP
Inai Park
Director
HK
Helen Kim
Director
PT
Peter Thompson
Director
Deka Biosciences, Inc. · Form D, Dec 8, 2023
JM
John Mumm
Chief Executive Officer and director
PK
Pavel Khrimian
Executive officer
DB
Detlev Biniszkiewicz
Director
LH
Lu Han
Director
CY
Christopher Yaen
Executive officer
PB
Peter Buzy
Director
Sources
- SECNextPoint Therapeutics, Inc. Form D, filed Jul 30, 2026
- SECSonoThera, Inc. Form D, filed Jun 30, 2026
- SECRecode Therapeutics, Inc. Form D, filed Oct 23, 2025
- SECDeka Biosciences, Inc. Form D, filed Dec 8, 2023
- Officialsonothera.com, board page
- Officialsonothera.com, Series B release (joined the board)